首页> 外文学位 >Sensitivity of MCF-7 breast cancer cells to anticancer drugs is decreased by activation of the PI3K/PDK/Akt signal transduction pathway.
【24h】

Sensitivity of MCF-7 breast cancer cells to anticancer drugs is decreased by activation of the PI3K/PDK/Akt signal transduction pathway.

机译:通过激活PI3K / PDK / Akt信号转导途径,MCF-7乳腺癌细胞对抗癌药物的敏感性降低。

获取原文
获取原文并翻译 | 示例

摘要

Activation of signal transduction pathways regulating cell cycle progression and apoptosis have been associated with both breast cancer development and resistance to anticancer agents. A more thorough understanding of the mechanisms by which these pathways contribute to breast cancer development and resistance to anticancer agents will be helpful for improving breast cancer treatment. Effects of activation of the PI3K/PDK/Akt cascade on in vitro sensitivity of MCF-7 human breast cancer cells to anticancer agents was investigated. Ectopic expression of mutant forms of PTEN lacking lipid phosphatase activity decreased sensitivity of MCF-7 cells to doxorubicin. Ectopic expression of Bcl-2 in MCF-7 cells also conferred doxorubicin resistance. Additionally, stimulation of Akt1 activity decreased sensitivity of MCF-7 cells to 4-HT. These results indicate that activation of the PI3K/PDK/Akt cascade decreases sensitivity of MCF-7 cells to anticancer agents. Furthermore, induction of Bcl-2 expression may contribute to anticancer drug resistance mediated by the PI3K/PDK/Akt pathway. Mechanisms regulating activity of the PI3K/PDK/Akt cascade in FDC-P1 murine myeloid hematopoietic progenitor cells were also identified. Activation of MEK1 or conventional and novel PKCs induced phosphorylation of Akts, which demonstrates that conventional and novel PKCs activate the PI3K/PDK/Akt cascade in FDC-P1 cells. Furthermore, it is possible that MEK1 contributes to activation of this pathway by conventional and novel PKCs. These findings indicate that activation of the PI3K/PDK/Akt cascade may contribute to the cytokine independence of FDC-P1 cells that proliferate in the presence of PMA.
机译:调节细胞周期进程和凋亡的信号转导通路的激活与乳腺癌的发展和对抗癌药的耐药性有关。对这些途径促成乳腺癌发展和抗癌药耐药性机制的更透彻理解将有助于改善乳腺癌的治疗。研究了PI3K / PDK / Akt级联激活对体外MCF-7人乳腺癌细胞对抗癌药敏感性的影响。缺乏脂质磷酸酶活性的PTEN突变形式的异位表达降低了MCF-7细胞对阿霉素的敏感性。 Bcl-2在MCF-7细胞中的异位表达也赋予了阿霉素抗性。此外,Akt1活性的刺激降低了MCF-7细胞对4-HT的敏感性。这些结果表明PI3K / PDK / Akt级联的激活降低了MCF-7细胞对抗癌药的敏感性。此外,Bcl-2表达的诱导可能有助于PI3K / PDK / Akt途径介导的抗癌药耐药性。还确定了调节FDC-P1小鼠骨髓造血祖细胞中PI3K / PDK / Akt级联活性的机制。 MEK1或常规和新型PKC的激活诱导了Akts的磷酸化,这表明常规和新型PKC激活了FDC-P1细胞中的PI3K / PDK / Akt级联。此外,MEK1可能通过传统的和新型的PKC促进了该途径的激活。这些发现表明,PI3K / PDK / Akt级联反应的激活可能会促进FMA-P1细胞的细胞因子独立性,而FDC-P1细胞在PMA存在时会增殖。

著录项

  • 作者

    Navolanic, Patrick M.;

  • 作者单位

    East Carolina University.;

  • 授予单位 East Carolina University.;
  • 学科 Biology Molecular.; Health Sciences Pharmacology.; Health Sciences Oncology.
  • 学位 Ph.D.
  • 年度 2004
  • 页码 151 p.
  • 总页数 151
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 分子遗传学;药理学;肿瘤学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号